Nicox SA, the French ophthalmology company, has received encouraging feedback from a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its new treatment, NCX 470. This milestone, announced on February 16, 2026, indicates that Nicox is on track to submit its NDA by summer 2026, following successful Phase 3 clinical trials.
NCX 470, a novel eye drop formulation designed to lower intraocular pressure in patients suffering from open-angle glaucoma or ocular hypertension, has demonstrated promising results, including a reduction in intraocular pressure by up to 10 mmHg. The FDA's acceptance of Nicox's current data package suggests a smoother path toward regulatory approval.
Positive FDA Feedback Fuels Progress
The FDA's written feedback from the pre-NDA meeting has confirmed that the proposed content and format of Nicox's NDA submission are generally acceptable. However, the agency has requested additional pharmacokinetic data, which Nicox plans to gather from a small cohort of patients participating in an ongoing study in Japan. This request is not expected to delay the NDA submission timeline.
Doug Hubatsch, Executive Vice President and Chief Scientific Officer of Nicox, expressed optimism about the meeting's outcome. "The productive and collaborative pre-NDA meeting with the FDA was conducted with our partner Kowa. The outcome supports the finalization of our registration dossier with its comprehensive data package, including positive results from two Phase 3 studies," he said. This partnership with Kowa is crucial, as they will take over the application process for the NDA submission.
Strategic Partnerships and Global Licensing
NCX 470 has been licensed globally to Kowa, a strategic move that allows Nicox to focus on its core strengths while leveraging Kowa's expertise in regulatory matters. Notably, the product is also licensed to Ocumension Therapeutics in China, South Korea, and Southeast Asia. This arrangement ensures that Nicox can expand its market reach while minimizing its financial burden, as all regulatory and commercialization costs will be managed by Kowa and Ocumension.
As Nicox progresses toward its NDA submission, it stands to gain significant financial rewards. The company is poised to receive milestone payments from Kowa upon submission of the NDA, along with royalties on global sales of NCX 470. This financial structure not only incentivizes Kowa but also underscores the potential market value of NCX 470, given its promising clinical data.
Upcoming Milestones for NCX 470
As the NDA submission approaches, several key milestones lie ahead for NCX 470. The company anticipates submitting the NDA in the United States during the summer of 2026, followed closely by a submission in China shortly thereafter. Additionally, the Phase 3 clinical program for NCX 470 in Japan is set to commence in the summer of 2025, expanding the treatment's reach and potential patient base.
These upcoming milestones are critical, as they not only represent steps toward market entry but also reflect Nicox's commitment to advancing its innovative treatment options in ophthalmology. By addressing the needs of patients with open-angle glaucoma and ocular hypertension, Nicox aims to make a significant impact on ocular health.
Nicox's Commitment to Ophthalmology Innovation
Founded in France, Nicox SA is dedicated to developing innovative solutions that enhance vision and ocular health. The company's flagship product, NCX 470, epitomizes its mission to combat serious eye conditions with novel therapeutic approaches. The eye drop leverages nitric oxide technology to provide a new treatment option for patients, which could transform management strategies for glaucoma and ocular hypertension.
With a strong pipeline and ongoing research efforts, Nicox is also exploring other potential therapies, including its preclinical program on NCX 177. The focus on innovation and collaboration with partners like Kowa positions Nicox favorably in the competitive pharmaceutical landscape.
As the company prepares for its NDA submission, stakeholders will be closely monitoring developments surrounding NCX 470. The upcoming months are poised to be pivotal, as Nicox navigates the regulatory landscape and aims to deliver a much-needed therapy to patients suffering from glaucoma and ocular hypertension.